Literature DB >> 24206237

ACE inhibitors and ARBs: do they reduce the risk of cancer?

Samuel J Mann1, Paul J Christos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24206237      PMCID： PMC8031651          DOI： 10.1111/jch.12225

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  7 in total

Review 1.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review.

Authors:  Úna C Mc Menamin; Liam J Murray; Marie M Cantwell; Carmel M Hughes
Journal:  Cancer Causes Control       Date:  2011-11-25       Impact factor: 2.506

Review 2.  Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

Authors:  Ilke Sipahi; Sara M Debanne; Douglas Y Rowland; Daniel I Simon; James C Fang
Journal:  Lancet Oncol       Date:  2010-06-11       Impact factor: 41.316

3.  Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.

Authors:  Sripal Bangalore; Sunil Kumar; Sverre E Kjeldsen; Harikrishna Makani; Ehud Grossman; Jørn Wetterslev; Ajay K Gupta; Peter S Sever; Christian Gluud; Franz H Messerli
Journal:  Lancet Oncol       Date:  2010-11-29       Impact factor: 41.316

4.  Use of angiotensin receptor blockers and the risk of cancer.

Authors:  Björn Pasternak; Henrik Svanström; Torbjörn Callréus; Mads Melbye; Anders Hviid
Journal:  Circulation       Date:  2011-04-11       Impact factor: 29.690

Review 5.  Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.

Authors: 
Journal:  J Hypertens       Date:  2011-04       Impact factor: 4.844

6.  Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension.

Authors:  Chin-Chou Huang; Wan-Leong Chan; Yu-Chun Chen; Tzeng-Ji Chen; Shing-Jong Lin; Jaw-Wen Chen; Hsin-Bang Leu
Journal:  Am J Cardiol       Date:  2011-01-20       Impact factor: 2.778

7.  Lowered cancer risk with ACE inhibitors/ARBs: a population-based cohort study.

Authors:  Yi-Ying Chiang; Kuen-Bao Chen; Tung-Han Tsai; Wen-Chen Tsai
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-11-08       Impact factor: 3.738
  7 in total
  3 in total

1.  Angiotensin II receptor blockers induce autophagy in prostate cancer cells.

Authors:  Yunseo Woo; Yu-Jin Jung
Journal:  Oncol Lett       Date:  2017-03-17       Impact factor: 2.967

2.  Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.

Authors:  Cheng-Maw Ho; Chih-Hsin Lee; Ming-Chia Lee; Jun-Fu Zhang; Jann-Yuan Wang; Rey-Heng Hu; Po-Huang Lee
Journal:  BMC Cancer       Date:  2018-04-10       Impact factor: 4.430

Review 3.  Medication use and risk of proximal colon cancer: a systematic review of prospective studies with narrative synthesis and meta-analysis.

Authors:  Rhea Harewood; Ruth Disney; James Kinross; Christian von Wagner; Amanda J Cross
Journal:  Cancer Causes Control       Date:  2021-07-05       Impact factor: 2.506
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.